New hope for advanced nasopharyngeal cancer: targeted radiation therapy under study
NCT ID NCT05198479
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called 177Lu-DOTATATE, which delivers radiation directly to cancer cells, in people with metastatic nasopharyngeal cancer that has not responded to at least two prior treatments. Only patients whose tumors show up on a special scan are eligible. The main goal is to see if the treatment can stop cancer from growing for at least 6 months.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC NASOPHARYNGEAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Cancer Centre Singapore
Singapore, Singapore
-
Singapore General Hospital
Singapore, Singapore